Digging Deeper Into the TP53 Mutation in AML with Rory Shallis, MD, Yale New Haven Hospital
IF YOU WOULD PREFER TO JOIN THE SHOW BY PHONE, PLEASE CALL (515) 602-9728
*You need to join by phone if you want to ask Dr. Shallis your questions.*
The TP53 mutation in AML is considered to be a high risk mutation and occurs in approximately 5-10% of patients. This genetic mutation has been difficult to treat, often being chemoresistant with a poor prognosis, however, the research indicates progress is being made in this area.
Join us live on Thursday, July 14th at 11 am EST to hear from Dr. Rory Shallis with Yale New Haven Hospital who will be discussing the TP53 mutation in AML, current treatment options available, and the latest research and clinical trials using novel investigational agents to target this mutation. There will be time at the end of the show to ask Dr. Shallis your questions directly!
Thank you to our episode sponsor, Bristol Myers Squibb.
Kerith Amen
Kerith joined HealthTree Foundation as a Community Co-Director for AML in 2022. She is a mother to a spirited eight-year-old daughter, Adair, and their beloved rescue, Violet. She lost her best friend and husband, Rob, to AML in March 2018. Kerith wishes she had a resource such as HealthTree for AML during Rob’s illness. She is a strong supporter of HealthTree's mission. She hopes that by sharing her experience, she may help other patients and caregivers navigate an AML diagnosis.
Rory Shallis, MD
Dr. Shallis is focused on the care and research of patients with myeloid malignancies, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). He currently participates as an investigator in several clinical trials aimed at improving the outcomes of patients with AML and MDS. He is an author on more than 75 peer-reviewed publications and book chapters, most of which he was first author on. His work has been published in many prestigious journals.